Mary M Chen

Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.

T. Chao, C. Ho, L. Yam, 2004 .

Tartrate-Resistant Acid Phosphatase 5b as a Serum Marker of Bone Metastasis in Breast Cancer Patients

T. Chao, C. Ho, L. Yam, 2004, Journal of Biomedical Science.

Tartrate-Resistant Acid Phosphatase 5b Activity Is a Useful Bone Marker for Monitoring Bone Metastases in Breast Cancer Patients after Treatment

Jyh‐cherng Yu, T. Chao, Chih-Hung Ku, 2006, Cancer Epidemiology Biomarkers & Prevention.

Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.

Jyh‐cherng Yu, T. Chao, Chih-Hung Ku, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Trial of Everolimus and Capecitabine in Metastatic HER2- Breast Cancer.

E. Guardino, G. Vidal, Shruti Sheth, 2017, Clinical breast cancer.

A feasibility study to evaluate breast cancer patients' knowledge of their diagnosis and treatment.

R. Balise, Stephanie M. Smith, A. Guardino, 2012, Patient education and counseling.

Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a.

T. Chao, D. Neustadt, Uzma A. Chaudhry, 2005, Clinica chimica acta; international journal of clinical chemistry.

Phase II trial combining paclitaxel with 24‐hour infusion cisplatin for chemotherapy‐naïve patients with locally advanced or metastatic breast carcinoma

Chiun-Sheng Huang, Chiun Hsu, A. Cheng, 2002, Cancer.

A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers

E. Guardino, G. Vidal, J. Ryder, 2017 .